Scientific Sessions 2024  /  Cutting-Edge Genetic and Precision Therapies in Cardiovascular Disease  /  Gene Therapy for Rare Cardiovascular Diseases
Logo

American Heart Association

  10
  0

Final ID:

Gene Therapy for Rare Cardiovascular Diseases

If you are unable to find a person you would like to add, enter their first name, last name, email, institution, role title, and Primary or Alternate below. Only add them once you have ensured you cannot find them in the AHA Database::
  • Mcnally, Elizabeth  ( NORTHWESTERN UNIVERSITY , Chicago , Illinois , United States )
  • Bursac, Nenad  ( DUKE UNIVERSITY, BIOMEDICAL ENGINEE , Durham , North Carolina , United States )
    • Author Disclosures:
    Elizabeth McNally: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Speaker:Regeneron:Past (completed) ; Ownership Interest:Ikaika Therapeutics:Active (exists now) ; Advisor:PepGen:Active (exists now) ; Advisor:Tenaya:Active (exists now) ; Consultant:Cytokinetics:Past (completed) | Nenad Bursac: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Cutting-Edge Genetic and Precision Therapies in Cardiovascular Disease

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Leveraging GWAS to Identify Novel Drug Targets

Bouatia-naji Nabila, Ganesh Santhi

siRNA for Treatment of Hypertension

Desai Akshay, Bakris George

More abstracts from these authors:
The JCI

Mcnally Elizabeth

Myosin Binding Protein C As A Target for Hypertrophic Cardiomyopathy

Mcnally Elizabeth, Carrier Lucie

You have to be authorized to contact abstract author. Please, Login
Not Available